Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/26015
Title: Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria
Authors: M. Van Vugt
S. Looareesuwan
P. Wilairatana
R. McGready
L. Villegas
I. Gathmann
R. Mull
A. Brockman
N. J. White
F. Nosten
Shoklo Malaria Research Unit
Academic Medical Centre, University of Amsterdam
Mahidol University
Ministry of Health
Novartis International AG
John Radcliffe Hospital
Keywords: Immunology and Microbiology;Medicine
Issue Date: 1-Jan-2000
Citation: Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.94, No.5 (2000), 545-548
Abstract: The efficacy and safety of the 6-dose regimen of artemether-lumefantrine were assessed in an open randomized trial in children and adults presenting with acute, uncomplicated Plasmodium falciparum malaria in Thailand between November 1997 and March 1998. 200 patients were enrolled in 2 centres: 150 received artemether-lumefantrine (i.e., a median total dose of 9.6 mg/kg [interquartile range 8.7-10.7] and 57.9 mg/kg of lumefantrine [52.4-64.0]) and 50 the standard combination of artesunate (12 mg/kg over 3 d) and mefloquine (25 mg/kg). All patients had rapid initial clinical and parasitological responses. The 28 d cure rates were high: 97.7% (95% confidence interval [95% CI] 93.5-99.5%) for artemether-lumefantrine and 100% (95% CI 92.5-100%) for artesunate-mefloquine. The 6-dose regimen of artemether-lumefantrine was better tolerated than, and as effective as, artesunate-mefloquine, the current standard treatment in this area of multidrug-resistant P. falciparum malaria.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033784974&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/26015
ISSN: 00359203
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.